Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Slideshows|July 1, 2019
The "Sweet Spot" in Type 2 Diabetes Management
Author(s)Payal Kohli, MD, FACC
The new "sweet spot" in diabetes management is the interdisciplinary approach that is essential to treating all aspects of the disease. New diabetes medications also hit that spot.
Advertisement
Advertisement
Related to this article
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
2
Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones
3
Multicomponent Strategies to Ease Vaccination Pain and Fear Across Ages
4
Real-World Nonhormonal Therapy Effects on VMS Bother, Work, and Mood
5